HealthRX Review: What to Know Before You Sign Up
An independent look at HealthRX pricing, its clinician-and-pharmacy model, compounded semaglutide and tirzepatide, and the tradeoffs to verify before paying.
Bottom line
HealthRX is a cash-pay telehealth marketplace for people considering compounded semaglutide or tirzepatide. Its public pricing is unusually specific, and its plans bundle clinician review, medication when prescribed and shipping. The key limitation is equally important: the products marketed in these plans are compounded preparations, not FDA-approved Wegovy, Ozempic, Zepbound or Mounjaro.
How HealthRX says the service works
HealthRX says it connects patients with independent U.S.-licensed clinicians and a licensed Section 503A compounding pharmacy. A clinician reviews the intake and determines whether treatment is clinically appropriate. HealthRX says it does not employ the doctors and does not own the pharmacy.
Current published pricing
| Medication | Lowest monthly equivalent | Plan behind that figure |
|---|---|---|
| Compounded semaglutide | $99/month | 12 months, $1,188 billed at published renewal pricing |
| Compounded tirzepatide | $179/month | 12 months, $2,148 billed at published renewal pricing |
HealthRX also publishes shorter plans at higher monthly-equivalent prices. Check the merchant page before checkout because current promotional and renewal amounts can change.
What the price includes
- Online medical consultation and clinician review
- Prescription when clinically appropriate
- Compounded medication
- Overnight shipping
- Provider messaging, dose management and refill coordination
- HealthRX says a full refund applies if a provider does not approve treatment
What deserves extra scrutiny
Do not evaluate this offer from headline price alone. Confirm the exact product prescribed, the clinician responsible for care, the dispensing pharmacy, the total amount billed today, renewal pricing, cancellation terms, storage instructions and what follow-up is available.
Compounded is not FDA-approved
FDA states that compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality. In 2026 FDA also reiterated restrictions that apply when compounded drugs are essentially copies of commercially available products. Those facts belong near the center of any HealthRX evaluation.
Who should compare another route
A different route may make more sense if your priority is an FDA-approved branded medicine, insurance coverage and prior authorization support, an established health system, or a shorter financial commitment.
Verdict
HealthRX is a legitimate comparison candidate for consumers specifically researching a cash-pay compounded telehealth model, but it should be compared as that model—not as a discount substitute for an FDA-approved branded product.
Considering HealthRX?
See the current HealthRX offer and eligibility process. If you use this link and make a qualifying purchase, GLP Clarity may earn a commission at no extra cost to you.
Check HealthRX eligibility →Sources
- HealthRX pricing
- HealthRX FAQ
- FDA: concerns with unapproved GLP-1 drugs
- FDA: 2026 compounding policy clarification
- FDA Wegovy prescribing information
- FDA Zepbound prescribing information
Provider prices and policies can change. We date-check unstable facts and distinguish provider claims from FDA or prescribing-information sources.